Sparsentan

Phase 2Active

2 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ANCA Associated Vasculitis

Conditions

ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases

Trial Timeline

Dec 8, 2022 → Sep 1, 2027

NCT ID

NCT05630612

About Sparsentan

Sparsentan is a phase 2 stage product being developed by Travere Therapeutics for ANCA Associated Vasculitis. The current trial status is active. This product is registered under clinical trial identifier NCT05630612. Target conditions include ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases.

What happened to similar drugs?

1 of 3 similar drugs in ANCA Associated Vasculitis were approved

Approved (1) Terminated (0) Active (2)

✅Avacopan, prednisolone and rituximab + Prednisolone and rituximabKissei PharmaceuticalApproved

🔄rituximab + PlaceboRochePhase 3

🔄Avacopan + Prednisone + Cyclophosphamide + Rituximab + AzathioprineAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07219121	Approved	Recruiting	Oct 7, 2025	May 1, 2027	Proteinuria
NCT05856760	Phase 2	Completed	May 19, 2023	Oct 25, 2024	Immunoglobulin A Nephropathy
NCT05630612	Phase 2	Active	Dec 8, 2022	Sep 1, 2027	ANCA Associated Vasculitis
NCT04663204	Phase 2	Active	Dec 10, 2020	Mar 31, 2025	Immunoglobulin A Nephropathy

Competing Products

10 competing products in ANCA Associated Vasculitis

See all competitors

Product	Company	Stage	Hype Score
Iptacopan + Placebo + Rituximab	Novartis	Phase 2	39
Rapcabtagene autoleucel + Glucocorticoids	Novartis	Phase 2	42
CellCept (mycophenolate mofetil)	Roche	Phase 1	29
rituximab + Placebo	Roche	Phase 3	40
Avacopan, prednisolone and rituximab + Prednisolone and rituximab	Kissei Pharmaceutical	Approved	50
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids	Amgen	Phase 2	35
Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine	Amgen	Phase 3	40
Abatacept (Orencia)	Bristol Myers Squibb	Phase 2	27
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy	Kyverna Therapeutics	Phase 1/2	33
FT819 + Fludarabine + Cyclophosphamide + Bendamustine	Fate Therapeutics	Phase 1	26